226 related articles for article (PubMed ID: 27758820)
1. ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.
Kim K; Li J; Barazia A; Tseng A; Youn SW; Abbadessa G; Yu Y; Schwartz B; Andrews RK; Gordeuk VR; Cho J
Haematologica; 2017 Feb; 102(2):246-259. PubMed ID: 27758820
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice.
Barazia A; Li J; Kim K; Shabrani N; Cho J
Blood; 2015 Nov; 126(22):2511-7. PubMed ID: 26265698
[TBL] [Abstract][Full Text] [Related]
3. Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease.
Li J; Jeong SY; Xiong B; Tseng A; Mahon AB; Isaacman S; Gordeuk VR; Cho J
Haematologica; 2020 Oct; 105(10):2407-2419. PubMed ID: 33054081
[TBL] [Abstract][Full Text] [Related]
4. The endothelin B receptor plays a crucial role in the adhesion of neutrophils to the endothelium in sickle cell disease.
Koehl B; Nivoit P; El Nemer W; Lenoir O; Hermand P; Pereira C; Brousse V; Guyonnet L; Ghinatti G; Benkerrou M; Colin Y; Le Van Kim C; Tharaux PL
Haematologica; 2017 Jul; 102(7):1161-1172. PubMed ID: 28385784
[TBL] [Abstract][Full Text] [Related]
5. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Jakubowski JA; Zhou C; Winters KJ; Lachno DR; Howard J; Payne CD; Mant T; Jurcevic S; Frelinger AL
Platelets; 2015; 26(5):474-9. PubMed ID: 25140584
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil AKT2 regulates heterotypic cell-cell interactions during vascular inflammation.
Li J; Kim K; Hahm E; Molokie R; Hay N; Gordeuk VR; Du X; Cho J
J Clin Invest; 2014 Apr; 124(4):1483-96. PubMed ID: 24642468
[TBL] [Abstract][Full Text] [Related]
7. Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin.
Canalli AA; Proença RF; Franco-Penteado CF; Traina F; Sakamoto TM; Saad ST; Conran N; Costa FF
Haematologica; 2011 Apr; 96(4):526-33. PubMed ID: 21173096
[TBL] [Abstract][Full Text] [Related]
8. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease.
Polanowska-Grabowska R; Wallace K; Field JJ; Chen L; Marshall MA; Figler R; Gear AR; Linden J
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2392-9. PubMed ID: 21071696
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.
Almeida CB; Scheiermann C; Jang JE; Prophete C; Costa FF; Conran N; Frenette PS
Blood; 2012 Oct; 120(14):2879-88. PubMed ID: 22833547
[TBL] [Abstract][Full Text] [Related]
10. Targeting Neutrophil Adhesive Events to Address Vaso-Occlusive Crisis in Sickle Cell Patients.
Morikis VA; Hernandez AA; Magnani JL; Sperandio M; Simon SI
Front Immunol; 2021; 12():663886. PubMed ID: 33995392
[TBL] [Abstract][Full Text] [Related]
11. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.
Yu Y; Savage RE; Eathiraj S; Meade J; Wick MJ; Hall T; Abbadessa G; Schwartz B
PLoS One; 2015; 10(10):e0140479. PubMed ID: 26469692
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.
Lebensburger JD; Howard T; Hu Y; Pestina TI; Gao G; Johnson M; Zakharenko SS; Ware RE; Tuomanen EI; Persons DA; Rosch JW
Blood; 2012 Feb; 119(8):1915-21. PubMed ID: 22130804
[TBL] [Abstract][Full Text] [Related]
13. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
Saleh AW; Hillen HF; Duits AJ
Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
[TBL] [Abstract][Full Text] [Related]
14. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.
Canalli AA; Franco-Penteado CF; Saad ST; Conran N; Costa FF
Haematologica; 2008 Apr; 93(4):605-9. PubMed ID: 18326523
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion.
Chang J; Shi PA; Chiang EY; Frenette PS
Blood; 2008 Jan; 111(2):915-23. PubMed ID: 17932253
[TBL] [Abstract][Full Text] [Related]
16. Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies.
Ferreira WA; Chweih H; Lanaro C; Almeida CB; Brito PL; Gotardo EMF; Torres L; Miguel LI; Franco-Penteado CF; Leonardo FC; Garcia F; Saad STO; Frenette PS; Brockschnieder D; Costa FF; Stasch JP; Sandner P; Conran N
J Pharmacol Exp Ther; 2020 Sep; 374(3):469-478. PubMed ID: 32631869
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia.
Benkerrou M; Delarche C; Brahimi L; Fay M; Vilmer E; Elion J; Gougerot-Pocidalo MA; Elbim C
Blood; 2002 Apr; 99(7):2297-303. PubMed ID: 11895759
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.
Jakubowski JA; Zhou C; Jurcevic S; Winters KJ; Lachno DR; Frelinger AL; Gupta N; Howard J; Payne CD; Mant TG
Thromb Res; 2014 Feb; 133(2):190-5. PubMed ID: 24368019
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
[TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Yu Y; Hall T; Eathiraj S; Wick MJ; Schwartz B; Abbadessa G
Anticancer Drugs; 2017 Jun; 28(5):503-513. PubMed ID: 28240679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
